Key result
Liposomal encapsulated anti-cancer agents represent an advanced and versatile drug delivery technology with several approved formulations for metastatic breast cancer and Kaposi's sarcoma.
Liposomal encapsulated anti-cancer agents represent a versatile drug delivery technology with several approved formulations for specific cancers.
Supports approved liposomal use in metastatic breast cancer and Kaposi's sarcoma; leaves open comparative trials for expanded indications.
Among several drug delivery systems, liposomal encapsulated anti-cancer agents represent an advanced and versatile technology. Several formulations of liposomal anthracyclines are approved, e.g. for the treatment of metastatic breast cancer (pegylated and non-pegylated liposomal doxorubicin) or AIDS-related Kaposi's sarcoma (pegylated liposomal doxorubicin and liposomal daunorubicin). Meanwhile, virtually all anti-cancer drugs have been encapsulated in liposomes using different technologies. This review will summarize preclinical and clinical data of approved and exemplary emerging liposomal anti-cancer agents.
No takes yet. Share an insight, caveat, or question.
Hofheinz et al. (2005) conducted a review in Cancer. Liposomal encapsulated anti-cancer drugs was evaluated. Liposomal encapsulated anti-cancer agents represent an advanced and versatile drug delivery technology with several approved formulations for metastatic breast cancer and Kaposi's sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on CardiomyopathyMore from Anti-Cancer Drugs